IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$37.89 USD
+0.31 (0.82%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $37.94 +0.05 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
IDYA 37.89 +0.31(0.82%)
Will IDYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IDYA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IDYA
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
IDYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
Company News for July 9, 2024
Other News for IDYA
Buy Rating Affirmed for IDEAYA Biosciences Amidst Strategic Advancements and Robust Pipeline Development
Ideaya Biosciences price target lowered by $3 at JPMorgan, here's why
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL) and IDEAYA Biosciences (IDYA)
Wedbush Remains a Buy on IDEAYA Biosciences (IDYA)
Oppenheimer Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)